177 related articles for article (PubMed ID: 29173008)
1. Monocyte-mediated chemotherapy drug delivery in glioblastoma.
Wang C; Li K; Li T; Chen Z; Wen Y; Liu X; Jia X; Zhang Y; Xu Y; Han M; Komatsu N; Zhao L; Chen X
Nanomedicine (Lond); 2018 Jan; 13(2):157-178. PubMed ID: 29173008
[TBL] [Abstract][Full Text] [Related]
2. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma.
Li TF; Li K; Zhang Q; Wang C; Yue Y; Chen Z; Yuan SJ; Liu X; Wen Y; Han M; Komatsu N; Xu YH; Zhao L; Chen X
Biomaterials; 2018 Oct; 181():35-52. PubMed ID: 30071380
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy.
Li TF; Xu YH; Li K; Wang C; Liu X; Yue Y; Chen Z; Yuan SJ; Wen Y; Zhang Q; Han M; Komatsu N; Zhao L; Chen X
Acta Biomater; 2019 Mar; 86():381-394. PubMed ID: 30654213
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the Design of Blood-Brain Barrier-Penetrating Polymer-Lipid-Hybrid Nanoparticles for Delivering Anticancer Drugs to Glioblastoma.
Ahmed T; Liu FF; He C; Abbasi AZ; Cai P; Rauth AM; Henderson JT; Wu XY
Pharm Res; 2021 Nov; 38(11):1897-1914. PubMed ID: 34655006
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.
Norouzi M; Yathindranath V; Thliveris JA; Kopec BM; Siahaan TJ; Miller DW
Sci Rep; 2020 Jul; 10(1):11292. PubMed ID: 32647151
[TBL] [Abstract][Full Text] [Related]
7. cRGD-directed, NIR-responsive and robust AuNR/PEG-PCL hybrid nanoparticles for targeted chemotherapy of glioblastoma in vivo.
Zhong Y; Wang C; Cheng R; Cheng L; Meng F; Liu Z; Zhong Z
J Control Release; 2014 Dec; 195():63-71. PubMed ID: 25108151
[TBL] [Abstract][Full Text] [Related]
8. High drug loading and pH-responsive targeted nanocarriers from alginate-modified SPIONs for anti-tumor chemotherapy.
Peng N; Wu B; Wang L; He W; Ai Z; Zhang X; Wang Y; Fan L; Ye Q
Biomater Sci; 2016 Nov; 4(12):1802-1813. PubMed ID: 27792228
[TBL] [Abstract][Full Text] [Related]
9. Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies.
Battaglia L; Gallarate M; Peira E; Chirio D; Muntoni E; Biasibetti E; Capucchio MT; Valazza A; Panciani PP; Lanotte M; Schiffer D; Annovazzi L; Caldera V; Mellai M; Riganti C
J Pharm Sci; 2014 Jul; 103(7):2157-2165. PubMed ID: 24824141
[TBL] [Abstract][Full Text] [Related]
10. Multiple emulsions as effective platforms for controlled anti-cancer drug delivery.
Dluska E; Markowska-Radomska A; Metera A; Tudek B; Kosicki K
Nanomedicine (Lond); 2017 Sep; 12(18):2183-2197. PubMed ID: 28820020
[TBL] [Abstract][Full Text] [Related]
11. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
[TBL] [Abstract][Full Text] [Related]
12. Facile development of nanocomplex-in-nanoparticles for enhanced loading and selective delivery of doxorubicin to brain.
Hefnawy A; Khalil IA; El-Sherbiny IM
Nanomedicine (Lond); 2017 Dec; 12(24):2737-2761. PubMed ID: 29135325
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.
Du K; Xia Q; Heng H; Feng F
ACS Appl Mater Interfaces; 2020 Aug; 12(31):34599-34609. PubMed ID: 32648735
[TBL] [Abstract][Full Text] [Related]
14. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
16. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Elastin-Like Polypeptides for Tumor Targeted Delivery of Doxorubicin to Glioblastoma.
Dragojevic S; Mackey R; Raucher D
Molecules; 2019 Sep; 24(18):. PubMed ID: 31489879
[TBL] [Abstract][Full Text] [Related]
18. RBC-derived vesicles as a systemic delivery system of doxorubicin for lysosomal-mitochondrial axis-improved cancer therapy.
Wu SH; Hsieh CC; Hsu SC; Yao M; Hsiao JK; Wang SW; Lin CP; Huang DM
J Adv Res; 2021 May; 30():185-196. PubMed ID: 34026295
[TBL] [Abstract][Full Text] [Related]
19. Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma.
Saha S; Yakati V; Shankar G; Jaggarapu MMCS; Moku G; Madhusudana K; Banerjee R; Ramkrishna S; Srinivas R; Chaudhuri A
J Mater Chem B; 2020 May; 8(19):4318-4330. PubMed ID: 32330214
[TBL] [Abstract][Full Text] [Related]
20. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
